6CM
LCTX icon

683 Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

683 Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-128,840
Closed -$193K – 215
2023
Q1 		$193K Hold
128,840
– – 0.01% 157
2022
Q4 		$151K Buy
+128,840
New +$162K 0.01% 219

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

683 Capital Management's LCTX Position: Q2 2023 in Review

683 Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 128,840 shares — an estimated $193K sold.

683 Capital Management first reported a position in LCTX in Q4 2022 and held it in 2 quarters. The position peaked at $193K in Q1 2023. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • 683 Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 128,840 Lineage Cell Therapeutics shares in Q2 2023, an estimated $193K.
  • 683 Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Lineage Cell Therapeutics position peaked at $193K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.